Prostate cancer's cruelest trait is its capacity to adapt — to render the very drugs designed to stop it obsolete. Researchers at the University of Eastern Finland have traced this adaptation to a molecular substitution, in which the glucocorticoid receptor quietly assumes the role of the androgen receptor, keeping tumors alive long after treatment should have prevailed. In mapping this process, the team identified two coregulator proteins, EP300 and CREBBP, whose inhibition may interrupt the resistance before it can take hold — offering a more precise foothold in the long struggle to keep adv
Finnish Study Identifies Coregulator Proteins as New Targets for Drug-Resistant Prostate Cancer
The cancer cells keep growing, but the drugs can't stop it anymore
Mark
So the basic problem is that prostate cancer drugs stop working. What's actually happening inside the cell when that occurs?
Mimi
The cancer cells are essentially switching out one driver for another. The androgen receptor, which most drugs target, gets replaced by the glucocorticoid receptor. The cell keeps growing, but the drugs can't stop it anymore.
Luke
And we know this happens, but do we know how often? Is this the main reason drugs fail, or one of several reasons?
Mimi
The study identifies it as a significant mechanism, but the source doesn't quantify how prevalent this particular pathway is across all drug-resistant cases.
Mark
The researchers found that blocking FOXA1 actually made things worse. That's surprising. Why would that happen?
Mimi
It revealed the complexity of the system. FOXA1 was assumed to be a brake on the glucocorticoid receptor, but when you remove it, the receptor becomes more active instead. The molecular interactions are more intricate than the simple model suggested.
Luke
So they were wrong about FOXA1's role. Did they test this in actual patient tumors, or only in lab cells?
Mimi
The work was done in laboratory cell cultures. That's an important distinction—what works in a dish doesn't always work in a living body.
Mark
Then they identified EP300 and CREBBP as targets. What makes these proteins different from FOXA1?
Mimi
These are coregulator proteins that work with the glucocorticoid receptor to enable drug resistance. When you inhibit them, the receptor's activity drops, and importantly, the androgen receptor gets suppressed too—especially in cells with amplified androgen receptor genes.
Luke
Small-molecule inhibitors showed promise. But have any of these inhibitors been tested in humans yet?
Mimi
The source doesn't mention human trials. This is still at the laboratory stage, identifying potential targets for future drug development.
Mark
So what's the practical next step for a patient with advanced prostate cancer right now?
Mimi
Right now, this research doesn't change treatment. But it maps out where future drugs might work, particularly for patients whose tumors have amplified androgen receptor genes.
El Pulso
- Prostate cancer drugs routinely stop working because tumors recruit a backup receptor — the glucocorticoid receptor — to sustain growth when the primary androgen receptor is blocked.
- A surprising finding upended assumptions: silencing FOXA1, a protein thought to restrain the glucocorticoid receptor, actually amplified its activity and deepened drug resistance.
- Two coregulator proteins, EP300 and CREBBP, emerged as essential enablers of this resistance mechanism, making them compelling targets for intervention.
- In laboratory studies, small-molecule inhibitors of EP300 and CREBBP suppressed both receptors simultaneously — and did so without triggering the molecular backlash that simpler approaches provoke.
- The strategy holds particular promise for patients whose tumors carry amplified androgen receptor genes, pointing toward more personalized treatment for advanced disease.
Prostate cancer's cruelest trait is its capacity to adapt — to render the very drugs designed to stop it obsolete. Researchers at the University of Eastern Finland have traced this adaptation to a molecular substitution, in which the glucocorticoid receptor quietly assumes the role of the androgen receptor, keeping tumors alive long after treatment should have prevailed. In mapping this process, the team identified two coregulator proteins, EP300 and CREBBP, whose inhibition may interrupt the resistance before it can take hold — offering a more precise foothold in the long struggle to keep advanced prostate cancer from outrunning medicine.
Prostate cancer has a grim talent for adaptation: the drugs used to fight it often stop working. Researchers at the University of Eastern Finland set out to understand why, and their findings point toward a way to prevent resistance before it begins.
The mechanism centers on a molecular substitution. Normally, the androgen receptor drives prostate cancer growth and serves as the primary drug target. But in resistant tumors, the glucocorticoid receptor — better known for its anti-inflammatory role — steps in to fill that function, allowing cancer cells to keep proliferating while therapies become useless. Mapping how this substitution operates at the genomic level was the study's first major task.
The results held surprises. FOXA1, a protein researchers had assumed would limit glucocorticoid receptor activity, did the opposite when inhibited — it intensified the receptor's function and worsened resistance. The finding underscored how deeply counterintuitive cancer's molecular logic can be.
More actionable was the identification of two coregulator proteins, EP300 and CREBBP, as essential partners in the glucocorticoid receptor's takeover. Silencing them in laboratory cells reduced glucocorticoid receptor activity and, critically, suppressed the androgen receptor as well — especially in cells with amplified androgen receptor genes, a common marker of advanced disease. Small-molecule inhibitors targeting these proteins showed early promise in blocking resistance from developing at all.
The approach also sidestepped the backlash problem: inhibiting EP300 and CREBBP restrained FOXA1 without triggering compensatory resistance. For men with advanced prostate cancer, particularly those whose tumors carry androgen receptor amplification, this research suggests that the next generation of effective therapies may need to operate one level deeper than the receptors themselves.
Prostate cancer kills men worldwide, and one of the cruelest facts about it is that the drugs we use to fight it often stop working. Researchers at the University of Eastern Finland have been studying why, and what they found points toward a new way to keep the disease from developing resistance in the first place.
The problem starts with a molecular swap. In healthy prostate cells, the androgen receptor drives growth and survival—it's the main target of most prostate cancer drugs. But when tumors become resistant, something shifts. The glucocorticoid receptor, a protein normally known for its anti-inflammatory work in the body, steps in and takes over the androgen receptor's job. The cancer cells keep growing, and the drugs that were supposed to stop them become useless. Understanding how this substitution happens at the molecular level was the first step toward stopping it.
Genome-wide studies revealed which regulatory regions of the cell's DNA were crucial to this process. The researchers looked at how the glucocorticoid receptor actually functions once it takes control, mapping out the molecular machinery that enables drug resistance. What they found was counterintuitive. A protein called FOXA1, which scientists had assumed would limit glucocorticoid receptor activity, actually did the opposite when inhibited—it made the receptor more active and worsened drug resistance. This unexpected result showed just how tangled the molecular interactions in cancer can be, and why simple solutions rarely work.
But the study also identified a different pathway, one that might be exploitable. Two coregulator proteins, EP300 and CREBBP, appeared to be essential partners in the glucocorticoid receptor's takeover. When the researchers silenced these proteins in laboratory cells, the glucocorticoid receptor's activity dropped. More importantly, silencing EP300 and CREBBP also suppressed the androgen receptor itself, particularly in cells that had amplified androgen receptor genes—a hallmark of advanced prostate cancer. Small-molecule inhibitors targeting these coregulator proteins showed promise in preventing drug resistance from developing in the first place.
The approach had another advantage. Inhibiting EP300 and CREBBP restrained FOXA1 activity without triggering the glucocorticoid receptor to compensate and drive resistance further. This suggested a novel strategy: target the coregulator proteins, and you could prevent resistance while avoiding the molecular backlash that simpler interventions might provoke.
These findings open a door toward personalized treatment. Not all prostate cancers are identical, and not all patients will benefit from the same approach. But for men whose tumors carry amplified androgen receptor genes—a common feature in advanced disease—targeting EP300 and CREBBP could offer a way to keep their cancer from becoming resistant to current therapies. The research represents a significant step forward in understanding the molecular architecture of drug resistance, and it suggests that the next generation of prostate cancer drugs may need to work at a deeper level than the receptors themselves.
Citas Notables
The glucocorticoid receptor can substitute for the androgen receptor, the main oncogenic factor, leading to drug resistance— University of Eastern Finland research findings
Silencing EP300 and CREBBP not only inhibited glucocorticoid receptor activity but also suppressed the androgen receptor, particularly in cells with androgen receptor gene amplification— Study results on coregulator protein inhibition
Quieres la nota completa?
Lee el original en TheHealthSite ↗
Health & Medicine